Gilead Sciences, Inc. (GILD) Faces its Greatest Threat to its Hepatitis C Drug: How Will That Impact Earnings? by Estimize
Gilead Sciences, Inc. (GILD) Healthcare – Biotechnology | Reports February 2, After Market Closes.
At this year's SALT New York conference, Jean Hynes, the CEO of Wellington Management, took to the stage to discuss the role of active management in today's investment environment. Hynes succeeded Brendan Swords as the CEO of Wellington at the end of June after nearly 30 years at the firm. Wellington is one of the Read More
- This quarter the Estimize consensus is more bullish than Wall Street, calling for EPS of $3.06 and revenue of $8.18 billion
- Gilead’s recent string of success can be attributed to the strength of its antiviral portfolio
- Merck recently launched a cheaper Hepatitis C drug which will put pressure Gilead’s margins and sales.
- What are you expecting for GILD? Get your estimate in here!